62 related articles for article (PubMed ID: 3264693)
1. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM
Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444
[TBL] [Abstract][Full Text] [Related]
2. Complement activation in infective endocarditis: correlation with extracardiac manifestations and prognosis.
Messias-Reason IJ; Hayashi SY; Nisihara RM; Kirschfink M
Clin Exp Immunol; 2002 Feb; 127(2):310-5. PubMed ID: 11876755
[TBL] [Abstract][Full Text] [Related]
3. Lupus nephritis.
Anders HJ; Saxena R; Zhao MH; Parodis I; Salmon JE; Mohan C
Nat Rev Dis Primers; 2020 Jan; 6(1):7. PubMed ID: 31974366
[TBL] [Abstract][Full Text] [Related]
4. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
5. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.
Merrill JT; Petri MA; Buyon J; Ramsey-Goldman R; Kalunian K; Putterman C; Conklin J; Furie RA; Dervieux T
Lupus Sci Med; 2018; 5(1):e000263. PubMed ID: 29868177
[TBL] [Abstract][Full Text] [Related]
6. Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.
Buyon J; Furie R; Putterman C; Ramsey-Goldman R; Kalunian K; Barken D; Conklin J; Dervieux T
Lupus Sci Med; 2016; 3(1):e000165. PubMed ID: 27752336
[TBL] [Abstract][Full Text] [Related]
7. New advances in measurement of complement activation: lessons of systemic lupus erythematosus.
Liu CC; Manzi S; Danchenko N; Ahearn JM
Curr Rheumatol Rep; 2004 Oct; 6(5):375-81. PubMed ID: 15355750
[TBL] [Abstract][Full Text] [Related]
8. Complement and systemic lupus erythematosus.
Walport MJ
Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S279-93. PubMed ID: 12110148
[TBL] [Abstract][Full Text] [Related]
9. Assessment of lupus: where are we now?
Hay E; Gordon C; Emery P
Ann Rheum Dis; 1993 Mar; 52(3):169-72. PubMed ID: 8484667
[TBL] [Abstract][Full Text] [Related]
10. Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?
Peakman M; Senaldi G; Vergani D
J Clin Pathol; 1989 Oct; 42(10):1018-25. PubMed ID: 2685048
[No Abstract] [Full Text] [Related]
11. Lupus nephritis. Middlesex, October 20, 1988. Abstracts.
Postgrad Med J; 1989 May; 65(763):336-43. PubMed ID: 2608573
[No Abstract] [Full Text] [Related]
12. Influence of C4 null alleles on C4 activation in systemic lupus erythematosus.
Briggs DC; Senaldi G; Isenberg DA; Welsh KI; Vergani D
Ann Rheum Dis; 1991 Apr; 50(4):251-4. PubMed ID: 2029208
[TBL] [Abstract][Full Text] [Related]
13. Relation between serological data at the time of biopsy and renal histology in lupus nephritis.
Nossent JC; Henzen-Logmans SC; Vroom TM; Huysen V; Berden JH; Swaak AJ
Rheumatol Int; 1991; 11(2):77-82. PubMed ID: 1947673
[TBL] [Abstract][Full Text] [Related]
14. Classical complement activation induced by pregnancy: implications for management of connective tissue diseases.
Hopkinson ND; Powell RJ
J Clin Pathol; 1992 Jan; 45(1):66-7. PubMed ID: 1740520
[TBL] [Abstract][Full Text] [Related]
15. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
Senaldi G; Makinde VA; Vergani D; Isenberg DA
Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
[TBL] [Abstract][Full Text] [Related]
16. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
18. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
Kao AH; Navratil JS; Ruffing MJ; Liu CC; Hawkins D; McKinnon KM; Danchenko N; Ahearn JM; Manzi S
Arthritis Rheum; 2010 Mar; 62(3):837-44. PubMed ID: 20187154
[TBL] [Abstract][Full Text] [Related]
19. Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis.
Qin S; Wang X; Wang J; Wu H
Lupus; 2024 Feb; 33(2):111-120. PubMed ID: 38227433
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
